Venus Remedies is currently trading at Rs. 274.15, up by 9.45 points or 3.57% from its previous closing of Rs. 264.70 on the BSE.
The scrip opened at Rs. 263.00 and has touched a high and low of Rs. 290.70 and Rs. 261.50 respectively. So far 121798 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 381.75 on 15-Sep-2014 and a 52 week low of Rs. 180.00 on 30-Sep-2013.
Last one week high and low of the scrip stood at Rs. 315.00 and Rs. 248.00 respectively. The current market cap of the company is Rs. 320.03 crore.
The promoters holding in the company stood at 37.51% while Institutions and Non-Institutions held 8.69% and 53.80% respectively.
Venus Remedies has entered into Singapore’s topical pain management market with a marketing authorization and patent for its herbal nanotechnology based pain reliever Trois. The company is holding talks with various pharmaceutical firms for tie-ups to market Trois in Singapore.
It is a great opportunity for the company to capture a sizeable share in this segment of the Singapore pharma market. Trois has a huge potential in Singapore, where 10% people are diagnosed with arthritis, 73.4% of the office workers suffer from musculoskeletal disorders and 20% of the population above the age of 65 suffers from symptoms of osteoarthritis.
Trois is the safest known topical product for management of pain and inflammation associated with rheumatic disorders. It is 30% more effective than conventional products, as proven through a series of toxicity and safety studies. It has 150% enhanced retention for longer effect, improved relief and better mobility
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: